Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia, A Retrospective Analysis from the Time of Transplant Approval

  • Rodríguez Arbolí, Eduardo|||0000-0002-2237-6733
  • Márquez-Malaver, F. J.
  • Rodríguez-Torres, N.
  • Caballero Velazquez, Teresa|||0000-0001-7487-3793
  • Escamilla-Gómez, V.
  • Calderón Cabrera, C.
  • Falantes, José Francisco|||0000-0001-8660-7038
  • Solé-Rodríguez, M.
  • García-Ramírez, P.
  • Moya-Arnao, María
  • Carreras, Enric|||0000-0002-3134-9964
  • Espigado, Ildefonso|||0000-0002-4043-6613
  • Pérez-Simón, José Antonio|||0000-0003-3616-6101
Clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-SCT) from unrelated donors (URDs) approach those of matched related donor (MRD) transplants in patients with acute myeloid leukemia (AML). Yet, available data fail to account for differences in pretransplantation outcomes between these donor selection strategies. In this regard, URD allo-HSCT is associated with longer waiting times to transplantation, potentially resulting in higher probabilities of failure to reach transplant. We retrospectively analyzed 108 AML patients accepted for first allo-HSCT from the time of approval to proceed to transplant. Fifty-eight (54%) patients were initially allocated to MRD, while URD search was initiated in 50 (46%) patients. Time to transplant was longer in patients allocated to a URD when compared with patients assigned to an MRD (median 142 days versus 100 days; p <.001). Forty-three of 58 (74%) patients in the MRD group and 35 of 50 (70%) patients in the URD group underwent transplantation (odds ratio [OR], 1.22; p =.63). Advanced disease status at the time of allo-HSCT approval was the only predictor of failure to reach transplantation in the multivariate analysis (OR, 4.78; p =.001). Disease progression was the most common cause of failure to reach allo-HSCT (66.7%) in both the MRD and URD groups. With a median follow-up from transplantation of 14.5 (interquartile range, 5 to 29) months, the 2-year estimate of overall survival (OS) from allo-HSCT was 46% in the MRD group and 57% in the URD group (p =.54). There were no differences in OS according to donor type allocation in the multivariate analysis (hazard ratio, 1.01; p =.83). When including patients from the time of transplant approval, 2-year OS was 39% in the MRD group versus 42% in the URD group. Our study suggests that allocation of AML patients to URDs may result in comparable clinical outcomes to MRD assignment without a significant increase in the risk of failure to reach transplant.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ruxolitinib in refractory acute and chronic graft-versus-host disease, a multicenter survey study

  • Escamilla Gómez, Virginia|||0000-0002-0639-574X
  • García Gutiérrez, Valentín|||0000-0003-4752-0815
  • López Corral, Lucia|||0000-0003-1908-5596
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Pérez Martínez, Ariadna
  • Márquez Malaver, Francisco J.|||0000-0002-6145-0414
  • Caballero Velazquez, Teresa|||0000-0001-7487-3793
  • González Sierra, Pedro A.
  • Viguria Alegría, María C.
  • Parra Salinas, Ingrid M.
  • Calderón Cabrera, C.
  • González Vicent, Marta
  • Rodríguez Torres, Nancy
  • Parody Porras, Rocío
  • Ferrá, Christelle|||0000-0003-4571-5125
  • Ortí, Guillermo|||0000-0002-7889-5807
  • Valcárcel, David|||0000-0002-8747-078X
  • de la Camara, Rafael|||0000-0002-8189-5779
  • Molés, Paula|||0000-0002-5005-0503
  • Velázquez-Kennedy, Kyra
  • João Mende, María
  • Caballero Barrigón, Dolores
  • Pérez, Estefanía|||0000-0003-0732-3235
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Saavedra Gerosa, Silvanna
  • Sierra, Jorge|||0000-0002-7966-0356
  • Poch, Marc
  • Zudaire Ripa, María T.
  • Díaz Pérez, Miguel A.
  • Molina Angulo, Blanca
  • Sánchez Ortega, Isabel
  • Sanz Caballer, Jaime
  • Montoro Gómez, Juan
  • Espigado Tocino, Ildefonso
  • Pérez-Simón, José Antonio|||0000-0003-3616-6101
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma, Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

  • Reinoso-Segura, Marta|||0000-0002-1859-9803
  • Caballero Velazquez, Teresa|||0000-0001-7487-3793
  • Herrera, Pilar|||0000-0002-4118-7110
  • Patriarca, Francesca
  • Fanin, Renato
  • Bruno, Benedetto
  • Einsele, Hermann
  • Nahi, Hareth
  • Granell, Miquel|||0000-0002-0366-3673
  • López Corral, Lucia|||0000-0003-1908-5596
  • Reguera, Juan L.
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Gahrton, Gösta
  • Pérez-Simón, José Antonio|||0000-0003-3616-6101
The use of reduced-intensity conditioning (RIC) regimens has decreased the risk of nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). In contrast, disease relapse remains the most frequent cause of treatment failure and death. Owing to both their antimyeloma effect and immunomodulatory properties, novel drugs could improve outcomes after alloSCT. This phase II European Myeloma Network trial was designed to evaluate the combination of alloSCT with novel agents. The study was conducted to evaluate the toxicity and efficacy of RIC intensified with bortezomib (Bz) prior to alloSCT for high-risk (HR) multiple myeloma (MM) patients, as well as the efficacy of post-transplantation maintenance with Bz and lenalidomide (Len). Patients received RIC with Bz on days -9 and -2, fludarabine on days -6 to -4, and melphalan on day -3. Patients who were in complete response (CR) or near CR at day +100 post-transplantation received 6 cycles of Bz every 56 days, and the remaining received Bz, Len, and dexamethasone. Len maintenance was started on day +180 at a dose of 5 mg and continued until relapse or toxicity occurred. Of the 24 patients included, 21 were evaluable on day +100, including 12 in CR, 4 in very good partial response, 3 in partial response, and 2 with relapse or progression. The cumulative incidence (CuI) of relapse was 13.6% (95% confidence interval [CI], 3.2% to 31.3%) at 1 year and 28.5% (95% CI, 11.1% to 48.9%) at 2 years. The CuI of NRM was 21.1% (95% CI, 7.4% to 39.4%) at 2 years. With a median follow-up of 39 months (range, 1 to 67 months), the median event-free survival (EFS) was 29 months, and median overall survival (OS) was not reached. EFS and OS at 3 years were 42.5% (95% CI, 21.9% to 61.7%) and 74.01% (95% CI, 50.9% to 87.5%), respectively. The use of Bz within an RIC regimen allows for a high response rate after alloSCT. Maintenance with Bz and Len is feasible and provides remarkable results in terms of EFS and OS in HR MM patients.